Get started
Author

Benoît Trottier

Observed names: B Trottier, B. Trottier, Benoit Trottier, Benôit Trottier, Trottier B, Trottier, B, Trottier, B., Trottier, Benoit
Observed institutions: Albert Einstein College of Medicine, Providence Health Care, Vita-Salute San Raffaele University, Inserm, Université du Québec à Montréal, McGill University Health Centre, Hôpital Notre-Dame, Roche (United Kingdom), Pitié-Salpêtrière Hospital, Gilead Sciences (United States), Centre Hospitalier de l’Université de Montréal, Hôtel-Dieu de Montréal, Hôpital Saint-Luc, Bicêtre Hospital, Québec-Océan, Research Institute of the McGill University Health Centre, BC Centre for Excellence in HIV/AIDS, McGill University, Concordia University, Université de Montréal, Drexel University, University of California, Davis
ORCID: 0000-0001-6133-8927
Observed ORCIDs: 0000-0001-6133-8927, 0000-0002-9285-848X
OpenAlex ID: A5003793199
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
2003 · Jacob P. Lalezari, Keith Henry, et al. · New England Journal of Medicine · 917
PDF
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
2015 · Paul E Sax, David Wohl, et al. · The Lancet · 601
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study
2017 · Jean-Michel Molina, Isabelle Charreau, et al. · The Lancet HIV · 472
PDF
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
2007 · Adriano Lazzarin, Thomas Campbell, et al. · The Lancet · 392
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
2008 · Gerd Fätkenheuer, Mark Nelson, et al. · New England Journal of Medicine · 365
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials
2005 · Mark Nelson, Keikawus Arastéh, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 153
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
2020 · Paul E Sax, Jürgen K Rockstroh, et al. · Clinical Infectious Diseases · 118
PDF
Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
2016 · Benoît Trottier, Jordan E Lake, et al. · Antiviral Therapy · 108
Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV ‐1 reservoirs: results from a multicentre randomized clinical study
2012 · JP Routy, CL Tremblay, et al. · HIV Medicine · 107
PDF
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
2010 · Christine Katlama, Bonaventura Clotet, et al. · Antiviral Therapy · 102
PDF
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
2021 · Onyema Ogbuagu, Peter J Ruane, et al. · The Lancet HIV · 89
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA
2016 · Jeffrey M. Jacobson, Jean-Pierre Routy, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 89
PDF
Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection
2019 · Vikram Mehraj, Rayoun Ramendra, et al. · Clinical Infectious Diseases · 83
PDF
Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks
2005 · Benoit Trottier, Sharon Walmsley, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 82
On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial
2019 · Guillemette Antoni, Cécile Tremblay, et al. · The Lancet HIV · 78
Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial
2006 · J. Gathe, D. A. Cooper, et al. · Clinical Infectious Diseases · 76
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
2005 · Julian Falutz, Soraya Allas, et al. · AIDS · 76
Covid-19 vaccine immunogenicity in people living with HIV-1
2022 · Lauriane Nault, Lorie Marchitto, et al. · Vaccine · 74
PDF
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
2023 · Onyema Ogbuagu, Onyema Ogbuagu, et al. · The Lancet HIV · 73
Envisioning Women-Centered HIV Care: Perspectives from Women Living with HIV in Canada
2017 · Nadia O'Brien, Saara Greene, et al. · Women s Health Issues · 73
PDF
HIV‐associated Lipodystrophy Syndrome: A Review of Clinical Aspects
2005 · Jean-Guy Baril, Patrice Junod, et al. · Canadian Journal of Infectious Diseases and Medical Microbiology · 71
PDF
Plasma Levels of C-Type Lectin REG3α and Gut Damage in People With Human Immunodeficiency Virus
2019 · Stéphane Isnard, Rayoun Ramendra, et al. · The Journal of Infectious Diseases · 70
PDF
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort
2015 · Réjean Thomas, Chrissi Galanakis, et al. · PLoS ONE · 69
PDF
Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts
2015 · Wei Cao, Vikram Mehraj, et al. · Clinical Infectious Diseases · 65
CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection
2019 · Vikram Mehraj, Rayoun Ramendra, et al. · Frontiers in Immunology · 59
PDF
Works count: 143
Citation count: 5,795
H-index: 35
I10-index: 70
Year
Topic
Type